Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.
Robert
R
Hoerster
Philipp
P
Muether
Claudia
C
Dahlke
Katrin
K
Mehler
André
A
Oberthür
Bernd
B
Kirchhof
Sascha
S
Fauser
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005865:Gestational Age; D006801:Humans; D052577:Infant, Extremely Low Birth Weight; D062071:Infant, Extremely Premature; D007231:Infant, Newborn; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab; D015861:Retinal Neovascularization / Q000097:blood* / Q000188:drug therapy; D012178:Retinopathy of Prematurity / Q000097:blood* / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000097:blood*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab